Abstract:Objective: To develop a multivariable signature to assist Parkinson’s disease diagnosis. Background: Parkinson’s disease (PD) pathology is characterized by neuromelanin loss and iron accumulation in substantia nigra pars compacta (SNc), as well as profound locus coeruleus (LC) degeneration. We have shown previously that neuromelanin-sensitive and iron-sensitive MRI sequences can robustly detect and quantify these phenomena (Huddleston DE, et al, 2017, PMID:28240402; Langley J, et al, 2017, PMID:27687624). No validated biomarkers for PD exist, and clinical diagnostic accuracy is sub-optimal in clinico-pathologic correlation studies. Neuroimaging tools are urgently needed to confirm PD neuropathology, assist clinical diagnosis, and enhance clinical trial recruitment. Design/Methods: 67 individuals (36 PD, 31 control) were studied at the Emory Movement Disorders Clinic under an IRB approved protocol with informed, written consent. MRI data were acquired using a Siemens Prisma-Fit 3T scanner. Neuromelanin-sensitive MRI (NM-MRI) and R2* (iron-sensitive MRI) acquisition and automated image processing to extract relevant features in SNc and LC were done using published methods (Langley J, et al, 2017, PMID: 27687624; Huddleston DE, et al, 2017, PMID: 28240402). The Movement Disorders Society UPDRS (MDS-UPDRS) Parts I and II questionnaires, the REM Sleep Behavior Disorder Questionnaire (RBDQ) and the Non-Motor Symptoms Questionnaire (NMSQ) were collected. With this dataset of extracted MRI and clinical features, logistic regression with elastic net (with 10-fold cross-validation) was used to train a classifier to accurately differentiate PD from controls. Sensitivity analysis was performed to identify informative features. Results: In a model including 6 MRI features of neuromelanin and iron pathology and 6 clinical features, receiver operating characteristic analysis revealed 94.2% diagnostic accuracy. Sensitivity analysis identified SNc volume, SNc R2*, MDS-UPDRS-II total score, and RBDQ item 2 (aggressive, action-packed dreams? yes/no) as the most informative features. Conclusions: This multivariable profile exhibits diagnostic accuracy in a potentially useful range for clinical and translational applications, and warrants further development. Disclosure: Dr. Huddleston has nothing to disclose. Dr. Mahmoudi has nothing to disclose. Dr. Langley has nothing to disclose. Dr. Factor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neurocrine, Lundbeck, Teva, Avanir, Sunovion, Adamas, Prexton, Biogen. Dr. Factor has received research support from Ipsen, Medtronics, Teva, US World Meds, Sunovion, Solstice, Vaccinex, Voyager, CHDI Foundation, Michael J. Fox Foundation, NIH. Dr. Crosson has nothing to disclose. Dr. Hu has nothing to disclose.

Diagnosing Parkinson's Disease by Combining Neuromelanin and Iron Imaging Features Using an Automated Midbrain Template Approach

An Automated Hybrid Approach Via Deep Learning and Radiomics Focused on the Midbrain and Substantia Nigra to Detect Early-Stage Parkinson’s Disease

Contribution and Clinical Significance of 3D and 2D Deep Learning and Radimoics Features Based on MR-T1W Images in Joint Diagnosis of Parkinson's Disease

Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging ‐based brain template

Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease

MRI Signature of Neuromelanin and Iron Pathology in Parkinson's Disease

A Multiple-Tissue-specific Magnetic Resonance Imaging Model for Diagnosing Parkinson's Disease: a Brain Radiomics Study.

Application of Neuromelanin MR Imaging in Parkinson Disease

Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI

Neuromelanin Detection by Magnetic Resonance Imaging (MRI) and Its Promise As a Biomarker for Parkinson’s Disease

An automated hybrid approach via deep learning and radiomics focused on the midbrain and substantia nigra to detect early-stage Parkinson's disease

Contrastive Machine Learning Reveals Parkinson’s Disease Specific Features Associated with Disease Severity and Progression

Region-Specific Iron Measured by MRI As a Biomarker for Parkinson’s Disease

Combined Visualization of Nigrosome-1 and Neuromelanin in the Substantia Nigra Using 3T MRI for the Differential Diagnosis of Essential Tremor and de novo Parkinson's Disease.

Different Iron Deposition Patterns in Early- and Middle-Late-onset Parkinson's Disease.

A Fully Automatic Framework for Parkinson’s Disease Diagnosis by Multi-Modality Images

Detecting Parkinsonian Degeneration in Lateroventral Tier of Substantia Nigra Pars Compacta with MRI

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Neuromelanin‐sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease

Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Nanoscale synchrotron x-ray analysis of intranuclear iron in melanised neurons of Parkinson's substantia nigra